UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000021240
Receipt number R000024350
Scientific Title Exploratory performance comparison trial of titanium allergy diagnostic agent
Date of disclosure of the study information 2016/03/01
Last modified on 2019/01/28 16:20:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory performance comparison trial of titanium allergy diagnostic agent

Acronym

Exploratory performance comparison trial of titanium allergy diagnostic agent

Scientific Title

Exploratory performance comparison trial of titanium allergy diagnostic agent

Scientific Title:Acronym

Exploratory performance comparison trial of titanium allergy diagnostic agent

Region

Japan


Condition

Condition

Titanium allergy

Classification by specialty

Dermatology Dental medicine Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To produce a diagnostic agent for titanium allergy

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Positive rate, negative rate, safety (rate of irritation response) and specificity to 0.1%, 0.5% titanium sulfate solution, 0.1% titanium chloride solution and oxidized titanium on the 7th day.

Key secondary outcomes

Expression frequency and rate of adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

Perform patch test to healthy person with titanium sulfate solution and titanimu chloride solution and oxidized titanium, it is judged according to the criteria of International Contact Dermatitis Research Group(ICDRG) on the second, third and seventh day.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1.Subjects who agree to participate for a week-long study.
2.Subjects who agree for a written informed consent for participating in this study.
3. Subjects without any symptoms of allergy (allergic dermatitis, palmoplantar pustulosis and lichen planus) and titanium allergy over the past decade.

Key exclusion criteria

1. Subjects who cannot interrupt the anti-allergic drugs from 3 days before patch test to date ended.
2. Subjects who have used corticosteroid medicine internally and/or externally within 1 month prior to the study.
3. Pregnant women and women of child bearing potential.
4. Subjects who cannot give informed consent.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hidemi Kurihara

Organization

Hiroshima University Hospital

Division name

Department of Periodontics and Endodontics

Zip code


Address

1-2-3 Kasumi, Minami-ku, Hiroshima

TEL

082-257-5663

Email

hkuri@hiroshima-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masae Kitagawa

Organization

Hiroshima University Hospital

Division name

Center of Oral Clinical Examination

Zip code


Address

1-2-3 Kasumi, Minami-ku, Hiroshima

TEL

082-257-5727

Homepage URL


Email

mhiraoka@hiroshima-u.ac.jp


Sponsor or person

Institute

Hiroshima University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 03 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 02 Month 10 Day

Date of IRB


Anticipated trial start date

2016 Year 03 Month 01 Day

Last follow-up date


Date of closure to data entry

2018 Year 11 Month 30 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 02 Month 29 Day

Last modified on

2019 Year 01 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024350


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name